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INTRODUCTION 
 
INTRODUCTION 
 
Diabetes during pregnancy is associated with increase in maternal and 
perinatal morbidity. The hallmark of this condition is increased insulin resistance. 
Maternal hormones are thought to interfere with the action of insulin as it binds to the 
insulin receptor. Since insulin promotes the entry of glucose into most cells, insulin 
resistance prevents glucose from entering the cells. As a result, glucose remains in the 
bloodstream, where glucose levels rise. More insulin is needed to overcome this 
resistance; more insulin is produced than in a normal pregnancy. Macrosomia
1
, 
congenital cardiac and central nervous system anomalies, skeletal malformations and 
respiratory distress syndrome are some of the well known complications occurring in 
infants of diabetic mothers. 
Moreover, human epidemiological and animal studies suggest that the 
intrauterine diabetic environment increases the risk of hypertension, obesity, and type 
II diabetes in adulthood in the offspring of diabetic mothers.  Fetal hyperinsulinemia 
at birth acts as a marker of this risk and it may also have potential prognostic 
implications. Thus, higher insulin levels in utero  might  be a cause   of later 
metabolic complications 
5,6,7
.  
Leptin is a hormone of adipose tissue that plays a key role in regulating energy 
intake and expenditure and the level of circulating leptin is directly proportional to the 
total amount of fat in the body. Leptin also has direct metabolic
 
effects on several 
tissues in promoting lipolysis.  Cord blood leptin correlates with measures of 
adiposity at birth
2,3,4
 and is also raised in offspring of mothers with diabetes 
3,4
.  
The interactions between leptin and insulin could  play a very important role 
in the pathogenesis of GDM and type 2 DM in pregnancy. So the  assessment of 
insulin and leptin at birth may be a particularly useful way of monitoring whether the 
fetus has been exposed to abnormally high levels of glucose in utero.
 
 
  We have measured the concentrations of C-peptide and leptin in cord blood 
together with birthweight and other anthropometric measures at birth.  The correlation 
between leptin, C-peptide and the anthropometric measures like birthweight, ponderal 
index and head circumference, is also assessed in this study. 
 
 
  
  
 
 
REVIEW OF 
LITERATURE 
 
  
REVIEW OF LITERATURE 
 
DIABETES MELLITUS 
 Diabetes mellitus (DM) refers to a group of common metabolic disorders that 
share the phenotype of hyperglycemia. Several distinct types of DM exist and are 
caused by a complex interaction of genetics and environmental factors. Depending on 
the etiology of the DM, factors contributing to hyperglycemia include reduced insulin 
secretion, decreased glucose utilization and increased glucose production. With an 
increasing incidence worldwide, DM will be a leading cause of morbidity and 
mortality for the foreseeable future. 
 
 
CLASSIFICATION 
 
 DM is classified on the basis of the pathogenic process that leads to 
hyperglycemia. The two broad categories of DM are designated type 1 and type 2.  
 
 Type 1 diabetes is the result of complete or near-total insulin deficiency. It is 
characterized by loss of the insulin-producing beta cells of the islets of 
Langerhans in the pancreas leading to insulin deficiency. This type of diabetes 
can be further classified as immune-mediated or idiopathic. The majority of 
type 1 diabetes is of the immune-mediated nature, where beta cell loss is a T-
cell mediated autoimmune attack.  
 
 Type 2 DM is a heterogeneous group of disorders characterized by variable 
degrees of insulin resistance, impaired insulin secretion and increased glucose 
production. Distinct genetic and metabolic defects in insulin action and/or 
secretion give rise to the common phenotype of hyperglycemia in type 2 DM. 
Type 2 DM is preceded by a period of abnormal glucose homeostasis 
classified as impaired fasting glucose (IFG) or impaired glucose tolerance 
(IGT). The disease is polygenic and multifactorial since in addition to genetic 
susceptibility, environmental factors (such as obesity, nutrition, and physical 
activity) modulate the phenotype. Most prominent is a variant of the 
transcription factor 7-like 2 gene that has been associated with type 2 diabetes 
in several populations. The mechanisms by which genetic alterations increase 
the susceptibility to type 2 diabetes are not clear, but they are predicted to alter 
insulin secretion. Investigation using genome-wide scanning for 
polymorphisms associated with type 2 DM is ongoing. 
 
 
 Gestational Diabetes Mellitus (GDM) - Glucose intolerance may develop 
during pregnancy. Insulin resistance is related to the metabolic changes of late 
pregnancy and the increased insulin requirements may lead to IGT. Most 
women revert to normal glucose tolerance post-partum but have a substantial 
risk (30–60%) of developing DM later in life. Gestational diabetes mellitus 
(GDM) resembles type 2 diabetes in several respects, involving a combination 
of relatively inadequate insulin secretion and responsiveness. Even though it 
may be transient, untreated gestational diabetes can damage the health of the 
fetus or mother. Risks to the baby include macrosomia (high birth weight), 
congenital cardiac and central nervous system anomalies, and skeletal muscle 
malformations. Increased fetal insulin may inhibit fetal surfactant production 
and cause respiratory distress syndrome. In fact, the rate of diabetes in 
expectant mothers has more than doubled in the past 6 years
5
 
 
 
DIAGNOSIS 
 The National Diabetes Data Group and World Health Organization have 
issued diagnostic criteria for DM  
 
 Symptoms of diabetes plus random blood glucose concentration >11.1 
mmol/L (200 mg/dL) or  
 Fasting plasma glucose > 7.0 mmol/L (126 mg/dL) or  
 Two-hour plasma glucose > 11.1 mmol/L (200 mg/dL) during an oral glucose 
tolerance test 
 
Glucose tolerance is classified into three categories based on the FPG  
 FPG < 5.6 mmol/L (100 mg/dL) is considered normal; 
 FPG = 5.6–6.9 mmol/L (100–125 mg/dL)  is defined as IFG; and  
 FPG >7.0 mmol/L (126 mg/dL) warrants the diagnosis of DM.  
 
 Based on the OGTT, IGT is defined as plasma glucose levels between 7.8 and 
11.1 mmol/L (140 and 199 mg/dL) and diabetes is defined as a glucose > 11.1 
mmol/L (200 mg/dL), 2 h after a 75-g oral glucose load. Some individuals have both 
IFG and IGT. Individuals with IFG and/or IGT, recently designated pre-diabetes by 
the American Diabetes Association (ADA), are at substantial risk for developing type 
2 DM (25–40% risk over the next 5 years) and have an increased risk of 
cardiovascular disease. 
 
 The current criteria for the diagnosis of DM emphasize that the FPG is the 
most reliable and convenient test for identifying DM in asymptomatic individuals. A 
random plasma glucose concentration >11.1 mmol/L (200 mg/dL) accompanied by 
classic symptoms of DM (polyuria, polydipsia, weight loss) is sufficient for the 
diagnosis of DM .Some investigators have advocated the hemoglobin A1C as a 
diagnostic test for DM. Though there is a strong correlation between elevations in the 
plasma glucose and the HbA1C , the relationship between the FPG and the A1C in 
individuals with normal glucose tolerance or mild glucose intolerance is less clear and 
thus the use of the A1C is not currently recommended to diagnose diabetes. 
 
TYPE 2 DIABETES MELLITUS 
RISK FACTORS 
 Family history of diabetes (i.e., parent or sibling with type 2 diabetes) 
 Obesity (BMI >25 kg/m2) 
 Habitual physical inactivity 
 Previously identified IFG or IGT 
 History of GDM or delivery of baby >4 kg (>9 lb) 
 Hypertension (blood pressure>140/90 mmHg) 
 HDL cholesterol level <35 mg/dL (0.90 mmol/L) and/or a triglyceride level 
>250 mg/dL (2.82 mmol/L) 
 Polycystic ovary syndrome or acanthosis nigricans 
 History of vascular disease 
 
 
 
PATHOPHYSIOLOGY 
 Type 2 DM is characterized by impaired insulin secretion, insulin resistance, 
excessive hepatic glucose production and abnormal fat metabolism. In the early stages 
of the disorder, glucose tolerance remains near-normal, despite insulin resistance, 
because the pancreatic beta cells compensate by increasing insulin output. As insulin 
resistance and compensatory hyperinsulinemia progress, the pancreatic islets in 
certain individuals are unable to sustain the hyperinsulinemic state. IGT, characterized 
by elevations in postprandial glucose, then develops. A further decline in insulin 
secretion and an increase in hepatic glucose production lead to overt diabetes with 
fasting hyperglycemia. Ultimately, beta cell failure may ensue. 
 
METABOLIC ABNORMALITIES 
Abnormal Muscle and Fat Metabolism 
 Insulin resistance, the decreased ability of insulin to act effectively on target 
tissues (especially muscle, liver, and fat), is a prominent feature of type 2 DM and 
results from a combination of genetic susceptibility and obesity. Insulin resistance 
impairs glucose utilization by insulin-sensitive tissues and increases hepatic glucose 
output; both effects contribute to the hyperglycemia. Increased hepatic glucose output 
predominantly accounts for increased FPG levels, whereas decreased peripheral 
glucose usage results in postprandial hyperglycemia. In skeletal muscle, there is a 
greater impairment in nonoxidative glucose usage (glycogen formation) than in 
oxidative glucose metabolism through glycolysis. Glucose metabolism in insulin-
independent tissues is not altered in type 2 DM. 
 
 The precise molecular mechanism leading to insulin resistance in type 2 DM 
has not been elucidated. Insulin receptor levels and tyrosine kinase activity in skeletal 
muscle are reduced, but these alterations are most likely secondary to 
hyperinsulinemia and are not a primary defect. Therefore, "postreceptor" defects in 
insulin-regulated phosphorylation / dephosphorylation  may play the predominant role 
in insulin resistance. For example, a PI-3-kinase signaling defect may reduce 
translocation of GLUT4 to the plasma membrane. Other abnormalities include the 
accumulation of lipid within skeletal myocytes, which may impair mitochondrial 
oxidative phosphorylation and reduce insulin-stimulated mitochondrial ATP 
production. Impaired fatty acid oxidation and lipid accumulation within skeletal 
myocytes may generate reactive oxygen species such as lipid peroxides. Of note, not 
all insulin signal transduction pathways are resistant to the effects of insulin (e.g., 
those controlling cell growth and differentiation using the mitogenic-activated protein 
kinase pathway). Consequently, hyperinsulinemia may increase the insulin action 
through these pathways, potentially accelerating diabetes-related conditions such as 
atherosclerosis. 
 
 
 The obesity accompanying type 2 DM, particularly in a central or visceral 
location, is thought to be part of the pathogenic process. The increased adipocyte 
mass leads to increased levels of circulating free fatty acids and other fat cell 
products. For example, adipocytes secrete a number of biologic products 
(nonesterified free fatty acids, leptin, resistin, and adiponectin). In addition to 
regulating body weight, appetite, and energy expenditure, adipokines also modulate 
insulin sensitivity. The increased production of free fatty acids and some adipokines 
may cause insulin resistance in skeletal muscle and liver. For example, free fatty acids 
impair glucose utilization in skeletal muscle, promote glucose production by the liver 
and impair beta cell function. In contrast, the production by adipocytes of adiponectin, 
an insulin-sensitizing peptide, is reduced in obesity and this may contribute to hepatic 
insulin resistance. Adipocyte products and adipokines also produce an inflammatory 
state and may explain why markers of inflammation such as IL-6 and C-reactive 
protein are often elevated in type 2 DM. 
 
 
 Insulin secretion and sensitivity are interrelated. In type 2 DM, insulin 
secretion initially increases in response to insulin resistance to maintain normal 
glucose tolerance. Initially, the insulin secretory defect is mild and selectively 
involves glucose-stimulated insulin secretion. The response to other nonglucose 
secretagogues, such as arginine, is preserved. Eventually,  the  insulin secretory defect 
progresses to a state of grossly inadequate insulin secretion. 
 
 
 The reasons for the decline in insulin secretory capacity in type 2 DM is 
unclear. The assumption is that a second genetic defect—superimposed upon insulin 
resistance—leads to beta cell failure. Islet amyloid polypeptide or amylin is 
cosecreted by the beta cell and forms the amyloid fibrillar deposit found in the islets 
of individuals with long-standing type 2 DM. Whether such islet amyloid deposits are 
a primary or secondary event is not known. The metabolic environment of diabetes 
may also negatively impact islet function. For example, chronic hyperglycemia 
paradoxically impairs islet function ("glucose toxicity") and leads to a worsening of 
hyperglycemia. Improvement in glycemic control is often associated with improved 
islet function. In addition, elevation of free fatty acid levels ("lipotoxicity") and 
dietary fat may also worsen islet function. Beta cell mass is decreased in individuals 
with long-standing type 2 diabetes. 
 
Increased Hepatic Glucose and Lipid Production 
 In type 2 DM, insulin resistance in the liver reflects the failure of 
hyperinsulinemia to suppress gluconeogenesis, which results in fasting hyperglycemia 
and decreased glycogen storage by the liver in the postprandial state. Increased 
hepatic glucose production occurs early in the course of diabetes, though likely after 
the onset of insulin secretory abnormalities and insulin resistance in skeletal muscle. 
As a result of insulin resistance in adipose tissue and obesity, free fatty acid (FFA) 
flux from adipocytes is increased, leading to increased lipid [very low density 
lipoprotein (VLDL) and triglyceride] synthesis in hepatocytes. This lipid storage or 
steatosis in the liver may lead to nonalcoholic fatty liver disease and abnormal liver 
function tests. This is also responsible for the dyslipidemia found in type 2 DM 
[elevated triglycerides, reduced high-density lipoprotein (HDL), and increased small 
dense low-density lipoprotein (LDL) particles]. 
 
GESTATIONAL DIABETES 
 
         Gestational diabetes is defined as "any degree of glucose intolerance with 
onset or first recognition during pregnancy"
18
. This definition includes the possibility 
that patients may have previously undiagnosed diabetes mellitus, or may have 
developed diabetes coincidentally with pregnancy. It is usually diagnosed by 
screening during pregnancy.  It is said to affect 3-10% of pregnancies, depending on 
the population studied
16
. No specific cause has been identified, but it is believed that 
the hormones produced during pregnancy increase a woman's resistance to insulin, 
resulting in impaired glucose tolerance. Most patients are treated only with diet 
modification and moderate exercise, but some take anti-diabetic drugs, including 
insulin 
17
. 
 
 The White classification, named after Priscilla White
20 
is widely used to assess 
maternal and fetal risk. It distinguishes between gestational diabetes (type A) and 
diabetes that existed prior to pregnancy (pregestational diabetes). These two groups 
are further subdivided according to their associated risks and management
21 
 
There are 2 subtypes of gestational diabetes (diabetes which began during pregnancy): 
 Type A1: abnormal oral glucose tolerance test (OGTT) but normal 
blood glucose levels during fasting and 2 hours after meals; diet 
modification is sufficient to control glucose levels  
 Type A2: abnormal OGTT compounded by abnormal glucose levels 
during fasting and/or after meals; additional therapy with insulin or 
other medications is required 
RISK FACTORS 
 
Classical risk factors for developing gestational diabetes are the following
22
:  
 A previous diagnosis of gestational diabetes or prediabetes, impaired 
glucose tolerance, or impaired fasting glycaemia  
 A family history revealing a first degree relative with type 2 diabetes  
 Maternal age - a woman's risk factor increases as she gets older 
(especially for women over 35 years of age)  
 Being overweight, obese or severely obese  
 A previous pregnancy which resulted in a child with a high birth weight 
>4000 g  
 
 
MECHANISMS BEHIND GDM 
 
 
 Insulin resistance is a normal phenomenon emerging in the second trimester of 
pregnancy, which progresses thereafter to levels seen in non-pregnant patients with 
type 2 diabetes. It is thought to secure glucose supply to the growing fetus. Women 
with GDM have an insulin resistance they cannot compensate with increased 
production in the β-cells of the pancreas. Placental hormones, and to a lesser extent 
increased fat deposits during pregnancy, seem to mediate insulin resistance during 
pregnancy. Cortisol, progesterone, human placental lactogen, prolactin and estradiol 
also play a role in insulin resistance
23
.  The following mechanisms are some of  the 
explanations for the development of GDM : autoimmunity, single gene mutations, 
obesity and other mechanisms
24
.  
 
 Because glucose travels across the placenta (through diffusion facilitated by 
GLUT3 carriers), the fetus is exposed to higher glucose levels. This leads  to 
increased fetal levels of insulin (insulin itself cannot cross the placenta). The growth-
stimulating effects of insulin can lead to excessive growth and a large body 
(macrosomia).  
 
 
 
 
 SCREENING TESTS FOR GESTATIONAL DIABETES 
 Non Challenge blood glucose tests 
o Fasting Glucose Test 
o 2-Hour Post Prandial  glucose test 
o  Random Glucose Test 
 Screening Glucose Challenge Test 
 Oral Glucose Tolerance Test (OGTT) 
 
NON-CHALLENGE BLOOD GLUCOSE TESTS 
 When a plasma glucose level is found to be higher than 126 mg/dl 
(7.0 mmol/l) after fasting, or over 200 mg/dl (11.1 mmol/l) on any occasion, and if 
this is confirmed on a subsequent day, the diagnosis of GDM is made and no further 
testing is required
19 
 
SCREENING GLUCOSE CHALLENGE TEST 
 The screening glucose challenge test (sometimes called the O'Sullivan test) is 
performed between 24–28 weeks, and can be seen as a simplified version of the oral 
glucose tolerance test (OGTT). It involves drinking a solution containing 50 grams of 
glucose, and measuring blood levels 1 hour later
19
. 
 
 If the cut-off point is set at 140 mg/dl (7.8 mmol/l), 80% of women with GDM 
will be detected.   If this threshold is lowered to 130 mg/dl, 90% of GDM cases will 
be detected, but there will also be more women who will be subjected to a consequent 
OGTT unnecessarily. 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 – Structure of Insulin and Proinsulin 
 ORAL GLUCOSE TOLERANCE TEST 
 The following are the values which the American Diabetes Association 
considers to be abnormal during the 100 g of glucose OGTT: 
 Fasting blood glucose level ≥95 mg/dl (5.33 mmol/L)  
 1 hour blood glucose level ≥180 mg/dl (10 mmol/L)  
 2 hour blood glucose level ≥155 mg/dl (8.6 mmol/L)  
 3 hour blood glucose level ≥140 mg/dl (7.8 mmol/L)  
An alternative test uses a 75 g glucose load and measures the fasting blood glucose 
levels and the levels after 1 and 2 hours, using the same reference values. This test 
will identify less women who are at risk, and there is only a weak concordance 
between this test and a 3 hour 100 g test. 
INSULIN 
 Insulin is a peptide hormone composed of 51 amino acids and has a molecular 
weight of 5808 Da. It is produced in the islets of Langerhans in the pancreas. The 
name comes from the Latin word  insula for "island".  The proinsulin precursor of 
insulin is encoded by the INS gene. 
 
STRUCTURE 
Insulin  (Figure 1) is produced and stored in the body as a hexamer, while the active 
form is the monomer. The hexamer is an inactive form with long-term stability, which 
serves as a way to keep the highly reactive insulin protected, yet readily available. 
The C-Peptide of proinsulin however, differs much more amongst species, it is also a 
hormone, but a secondary one. 
The C-peptide of  proinsulin however, differs much more amongst species; it is also a 
hormone, but a secondary one 
 
 
 
 
 
 
 
 
 
 
   
Figure 2 - Insulin Biosynthesis 
 BIOSYNTHESIS 
 
 Insulin is produced in the beta cells of the pancreatic islets ((Figure 2). It is 
initially synthesized as a single-chain 86-amino-acid precursor polypeptide, 
preproinsulin. Subsequent  proteolytic  processing removes the aminoterminal signal 
peptide, giving rise to proinsulin.  Proinsulin is structurally related to insulin-like 
growth factors I and II, which bind weakly to the insulin receptor. Cleavage of an 
internal 31-residue fragment from proinsulin generates the C-peptide and the A (21 
amino acids) and B (30 amino acids) chains of insulin, which are connected by 
disulfide bonds. The mature insulin molecule and C-peptide are stored together and 
cosecreted from secretory granules in the beta cells. Because the C-peptide is cleared 
more slowly than insulin, it is a useful marker of insulin secretion and allows 
discrimination of endogenous and exogenous sources of insulin in the evaluation of 
hypoglycemia. Pancreatic beta cells cosecrete islet amyloid polypeptide (IAPP) or 
amylin, a 37-amino-acid
 
peptide, along with insulin. The role of IAPP in normal 
physiology is unclear, but it is the major component of the amyloid fibrils found in the 
islets of patients with type 2 diabetes and an analogue is sometimes used in treating 
both type 1 and type 2 DM. 
The endogenous production of insulin is regulated in several steps along the synthesis 
pathway: 
 At transcription from the insulin gene  
 In mRNA stability  
 At the mRNA translation and 
In the post translational modifications 
 
  
 
 
 
 
  Figure 3 - Mechanism of Insulin Release 
RELEASE 
 
  Beta cells in the islets of Langerhans release insulin in two phases. The first 
phase insulin release is rapidly triggered in response to increased blood glucose 
levels. The second phase is a sustained, slow release of newly formed vesicles that are 
triggered independently of sugar. The description of first phase release is as follows 
((Figure 3): 
 Glucose enters the beta cells through the glucose transporter GLUT2  
 Glucose goes into glycolysis and the respiratory cycle where multiple high-
energy ATP molecules are produced by oxidation  
 Dependent on the ATP:ADP ratio and hence blood glucose levels, the ATP-
dependent potassium channels (K+) close and the cell membrane depolarizes  
 On depolarization, voltage controlled calcium channels (Ca
2+
) open and 
calcium flows into the cells  
 An increased calcium level causes activation of phospholipase C, which 
cleaves the membrane phospholipid phosphatidyl inositol 4,5-bisphosphate 
into inositol 1,4,5-triphosphate and diacylglycerol.  
 Inositol 1,4,5-triphosphate (IP3) binds to receptor proteins in the membrane of 
endoplasmic reticulum (ER). This allows the release of Ca
2+
 from the ER via 
IP3 gated channels, and further raises the cell concentration of calcium.  
 Significantly increased amounts of calcium in the cells causes release of 
previously synthesized insulin, which has been stored in secretory vesicles  
 
ACTION 
Insulin binding to its receptor stimulates intrinsic tyrosine kinase activity, leading to 
receptor autophosphorylation and the recruitment of intracellular signaling 
   
Figure 4 - Insulin Signal Transduction Pathway in Skeletal Muscle 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 5 - Effect of Insulin on Glucose Metabolism 
molecules, such as insulin receptor substrates (IRS). IRS and other adaptor proteins 
initiate a complex cascade of phosphorylation and dephosphorylation reactions, 
resulting in the widespread metabolic and mitogenic effects of insulin  (Figure 4). As 
an example, activation of the phosphatidylinositol-3'-kinase (PI-3-kinase) pathway 
stimulates translocation of glucose  
transporters (e.g., GLUT4) to the cell surface, an event that is crucial for glucose 
uptake by skeletal muscle and fat. Activation of other insulin receptor signaling 
pathways induces  
glycogen synthesis, protein synthesis, lipogenesis and regulation of various genes in 
insulin-responsive cells. 
 
EFFECT OF INSULIN ON GLUCOSE METABOLISM 
 Insulin binds to its receptor, which in turn starts many protein activation 
cascades. These include translocation of Glut-4 transporter to the plasma membrane 
and influx of glucose, glycogen synthesis, glycolysis and fatty acid synthesis  (Figure 
5). 
 
DEGRADATION 
It  has been estimated that an insulin molecule produced endogenously by the 
pancreatic beta cells is degraded within approximately one hour after its initial release 
into circulation (insulin half-life ~ 4–6 minutes)11,12. 
C-PEPTIDE 
  C-peptide was first described in 1967 in connection with the discovery of the 
insulin biosynthesis
13
. It serves as an important linker between the A and the B chains 
of insulin and facilitates the efficient assembly, folding, and processing of insulin in 
  
Figure 6 - Structure of C-peptide 
 the endoplasmic reticulum. Equimolar amounts of C-peptide and insulin are then 
stored in secretory granules of the pancreatic beta cells and both are eventually 
released to the portal circulation. Initially, the sole interest in C-peptide was as a 
marker of insulin secretion and it has been of great value in further understanding of 
the pathophysiology of type 1 and type 2 diabetes. The first documented use of the C-
peptide test was in 1972. During the past decade, however, C- 
peptide has been found to be a bioactive peptide in its own right, with effects on 
microvascular blood flow and tissue health (Figure 6). 
 
FUNCTION 
 C-peptide has been shown to bind to the surface of a number of cell types such 
as neuronal, endothelial, fibroblast and renal tubular, at nanomolar concentrations to a 
receptor that is likely G-protein coupled. The signal activates Ca2+ dependent 
intracellular signaling pathways such as MAPK, PLCγ and PKC, leading to 
upregulation of a range of transcription factors as well as eNOS and Na+K+ATPase 
activities
14
. The latter two enzymes are known to have reduced activities in patients 
with type I diabetes and have been implicated in the development of long-terms 
complications of type I diabetes such as peripheral and autonomic neuropathy. In vivo 
studies in animal models of type 1 diabetes have established that C-peptide 
administration results in significant improvements in nerve and kidney function. C-
peptide has also been reported to have anti-inflammatory effects and it aids in repair 
of smooth muscle cells
15
. 
LEPTIN 
 Leptin (Greek leptos meaning thin) is a 16 kDa protein hormone that plays a 
key role in regulating energy intake and energy expenditure, including appetite and  
   
Figure 7  - Structure of Leptin 
  
Figure 8 - Central Connections of Leptin 
metabolism. It is one of the most important adipose derived hormones
25 
 (Figure 7). 
The Ob(Lep) gene (Ob for obese, Lep for leptin) is located on chromosome 7 in 
humans
26
. 
DISCOVERY 
 The effects of leptin were observed by studying mutant obese mice that arose 
at random within a mouse colony at the Jackson Laboratory in 1950
27
. These mice 
were  massively obese and excessively voracious. Ultimately, several strains of 
laboratory mice have been found to be homozygous for single-gene mutations that 
causes them to become grossly obese, and they fall into two classes: "ob/ob", those 
having mutations in the gene for 
the protein hormone leptin and "db/db", those having mutations in the gene that 
encodes the receptor for leptin. When ob/ob mice are treated with injections of leptin, 
they lose their excess fat and return to normal body weight.  Leptin  was discovered in 
1994 by Jeffrey M. Friedman and colleagues at the Rockefeller University through the 
study of such mice
28
. 
 
ACTIONS ON HYPOTHALAMUS 
Leptin acts on receptors in the hypothalamus of the brain where it inhibits appetite by  
 Counteracting the effects of neuropeptide Y (a potent feeding stimulant 
secreted by cells in the gut and in the hypothalamus) 
 Counteracting the effects of anandamide (another potent feeding stimulant)    
 Promoting the synthesis of α-MSH, an appetite suppressant  (Figure 8) 
 
 The absence of leptin (or its receptor) leads to uncontrolled food intake and 
resulting obesity. Thus, circulating leptin levels give the brain,  input regarding   
energy storage . Leptin works by inhibiting the activity of neurons that contain 
neuropeptide Y (NPY) and agouti-related peptide (AgRP) and by increasing the 
activity of neurons expressing α-melanocyte-stimulating hormone (α-MSH). The 
NPY neurons are a key element in the regulation of appetite; small doses of NPY 
injected into the brains of experimental animals stimulates feeding, while selective 
destruction of the NPY neurons in mice causes them to become anorexic. Conversely, 
α-MSH is an important mediator of satiety and differences in the gene for the receptor 
at which α-MSH acts in the brain are linked to obesity in humans. 
 
SEXUAL DIMORPHISM OF LEPTIN  
 Sexual dimorphism of leptin in humans is evident in both ob mRNA 
expression
29,30
 and in the correlation between leptin concentrations and fat mass 
31,32
. 
Kennedy and co-workers
32
 proposed that the observed gender differences in leptin 
synthesis are because of the stimulating roles of oestrogens and/or a suppressive effect 
of circulating androgens, while other authors have been unable to find a correlation 
between sexual dimorphism of leptin and sex hormones. 
 
SYNTHESIS 
 Leptin is translated as a 167 amino acid protein with an amino-terminal 
secretory signal sequence of 21 amino acids. The signal sequence is functional and 
results in the trans-location of leptin into microsomes with the subsequent removal of 
the signal peptide. Therefore, leptin circulates in the blood as protein of 146 amino 
acid residues. 
 
  It is manufactured primarily in the adipocytes of white adipose tissue and the 
level of circulating leptin is directly proportional to the total amount of fat in the 
body. In addition to white adipose tissue—the major source of leptin—it can also be 
produced by brown adipose tissue, placenta (syncytiotrophoblasts), ovaries, skeletal 
muscle, stomach (lower part of fundic glands), mammary epithelial cells, bone 
marrow, pituitary and liver.
33
   Leptin has also been discovered to be synthesised from 
gastric chief cells in the stomach
34
.  
SITES OF LEPTIN SYNTHESIS 
WHITE ADIPOSE TISSUE 
 White adipose tissue (WAT) is the main site of leptin synthesis, but it is now 
evident that the hormone is produced in other tissues as well. There is some evidence 
that brown adipose tissue (BAT) is also a site of leptin production
35-42
. A major issue 
is the physiological role of leptin produced by brown fat.  If the ob gene is expressed 
by brown adipocytes, then there are important implications for the physiological role 
of leptin. One possibility is that it simply adds to the pool of circulating hormone and 
thus its contribution would be small relative to that of white fat in mature animals and 
man
43
. Other reports suggest that the expression that is observed may be a reflection 
of contamination or infiltration of brown fat with white adipocytes
44
. However, 
Moinat et al
35
 reported that the level of mRNA in interscapular brown fat was about 
40% of that in the epididymal white fat depot, a result that is unlikely to be explained 
by infiltration or contamination. If the ob gene is expressed by brown adipocytes, then 
there are important implications for the physiological role of leptin.  
 
 Comparison of the levels of ob mRNA in different adipose tissue depots 
suggests that there are site-specific variations in the expression of the ob gene in both 
rodents
44,45
 and humans
47,48
. In humans
46
, leptin expression appears to be greater in 
subcutaneous than in omental adipose tissue
47,48
.  The differences in mRNA level 
between various adipose tissue sites may reflect differences in fat cell size; the larger 
the adipocytes, the greater the expression of the ob gene
44,45,46,49
. However, Lonnqvist 
et al using in situ hybridization, found no differences in leptin expression between 
subcutaneous and omental fat in a small group of four obese humans. 
 
 In rodents the opposite is apparent as leptin expression may be lower in 
subcutaneous fat than in the internal depots and the highest level of expression is 
generally evident in the epididymal (males) and perirenal adipose tissues
45,47
. 
However, site-specific leptin expression also varies with maturation as in adult 
rodents; the ob mRNA level is much higher in the gonadal and perirenal sites than in 
subcutaneous depots,
44
 but in suckling rats during the first 2 weeks after birth, the 
subcutaneous fat is the main site of ob gene expression. 
 
PLACENTA 
 An important new dimension to leptin biology has emerged with the 
recognition that the placenta and ovary express the leptin gene and that they are sites 
of production of the hormone.  This has been demonstrated in mice, rats and 
humans
50-53
.  
 
 Two hypotheses about the role of placental synthesis of leptin are that it may 
either be a new growth factor, or act as a signal of energy status between the mother 
and the fetus. The placenta also expresses the leptin receptor gene, implying that the 
organ is a target for the action of leptin in addition to being a source of the hormone
50
.   
These observations suggest that leptin may act in an autocrine manner. The 
expression of leptin by syncytiotrophoblasts
50,55,56
 has added support to the hypothesis 
of the importance of leptin in nutrient transfer. 
 
FETAL TISSUES 
  In situ hybridization and immunohistochemical studies on pregnant mice have 
demonstrated leptin synthesis in several regions of the fetus, including the heart, bone 
and cartilage, choroid plexus of the fetal brain, lung, kidney, heart and liver  and the  
cells of the hair follicle
57
. 
 
LIVER 
 Studies have reported that leptin gene expression in chicken was not only 
localized in adipose tissue, as in mammals, but also in liver. The expression of leptin 
in liver may be associated with a key role of this organ in avian species in controlling 
lipogenesis. The diverse picture of where leptin is produced in the body indicates that 
the functions of the hormone may extend beyond the basic lipostatic model  
 
REGULATION OF LEPTIN SYNTHESIS 
ENERGY EXCESS 
 The level of ob mRNA in white adipose tissue and the circulating leptin 
concentration are increased markedly in obesity, as shown in both human studies and 
in studies of several types of obese animals
46,58,59,60
. Indeed, in human subjects there is 
a high correlation between body mass index (BMI) and circulating leptin
46
. Thus, the 
greater the amount of adipose tissue, the higher the level of the hormone. In addition, 
adipocyte size appears to be another major determinant of leptin mRNA expression
61
. 
Hormonal factors have also been studied in relation to leptin and are discussed below. 
 FASTING 
 Changes in physiological state induced by fasting result in reduced ob gene 
expression and a subsequent fall in circulating leptin
44,62,63
.  Rapid decreases in leptin 
levels in response to energy restriction or fasting appear to be greater than the 
decrease in fat mass in both rodents
58
 and humans
64
.  
 
 Thus, leptin may serve as a sensor of short-term changes in energy stores. 
Another study in mice has shown that re-feeding after fasting led to a rapid restoration 
of gene expression and plasma leptin
66
. The inhibitory effect of fasting on leptin 
expression might also be mediated by the sympathetic nervous system and the 3-
AR.  
 
REGULATION OF LEPTIN GENE EXPRESSION 
 The sympathetic nervous system, especially the -AR axis, has been 
implicated in the regulation of leptin gene expression. For example, the -AR 
agonists, noradrenaline and isoprenaline decreased leptin gene expression in WAT in 
mice
65
 and decreased serum leptin.
67
 It has been shown, both in vivo and in vitro, that 
3-agonists induce a decrease in the expression of leptin in WAT and BAT and 
decrease serum leptin.
43,65,68,69,70
 The significance of 3-AR in the control of leptin 
production in human subjects is uncertain, although there is evidence that the receptor 
may play an important role in the control of lipolysis in human omental and 
subcutaneous adipose tissue
71,72
.  Mantzoros et al
68
 reported that acute treatment of 
mice with the 3-agonist, suppressed leptin expression in WAT. Thus it appears that 
the leptin response to specific 3-AR activation is analogous to classical adrenergic 
activation.   In addition, leptin has been shown to increase noradrenaline turnover in 
thermogenic interscapular BAT
73
 and to also increase the sympathetic outflow to 
other tissues
74,75
. 
 
ROLE OF LEPTIN IN ENERGY EXPENDITURE 
  Leptin is involved in increased energy utilization, possibly through enhanced 
thermogenesis mediated by tissue uncoupling proteins (UCPs). Studies on UCP 
subtype expression in rodents have shown that UCP-1 is expressed at higher levels 
during cold exposure and decreased by fasting
76
 and that leptin treatment enhances
77
 
or does not alter BAT UCP-1 mRNA, compared with untreated controls. 
 
OB-RECEPTOR (LONG AND SHORT FORMS)  
 Leptin interacts with six types of receptors (Ob-Ra–Ob-Rf, or LepRa-LepRf) 
which in turn are encoded by a single gene, LEPR
80
. Ob-R exhibit a widespread 
distribution including liver, heart, kidneys, lungs, small intestine, testes, ovaries, 
spleen, pancreas and adipose tissue
79,50,81,82,83,84.85
.  However, analysis has shown that 
the majority of transcripts detected are those encoding short intracellular domain 
forms
81,82
.  Within the hypothalamus, the long form leptin receptor has been found in 
several hypothalamic nuclei, including the arcuate nucleus, ventromedial, 
dorsomedial, lateral hypothalamic nuclei and the paraventricular nucleus.  
 
 All isoforms of the murine leptin receptor share an identical extracellular, 
ligand-binding domain of 816 amino acids, while the intracellular domain at the C-
terminus is different
86,79
 Ob-Ra, Ob-Rb, Ob-Rc, Ob-Rd and Ob-Rf contain 
transmembrane domains of 34 amino acids, whereas Ob-Re is truncated before the 
membrane-spanning domain and is therefore likely to be secreted.
79
 Secreted 
extracellular domains of other cytokine receptors are also known to function as 
specific binding proteins.
88
 Ob-Rb (the human form of which is also referred to as 
Ob-RL; L=long) has a long cytoplasmic domain of 320 amino acids. Recently, 
another splice variant of leptin receptor, B219, was cloned from murine fetal liver.
89
 
Ob-Rb is the only receptor isoform that can signal intracellularly via the Jak-Stat and 
MAPK signal transduction pathways
87
 
 
Ob-Receptor induced signal transduction 
 Upon leptin binding to its receptor, receptor dimerisation occurs, which seems 
to be necessary for signaling activity
90,91,92
. After leptin binding and receptor 
homodimerization, the long form of the receptor (Ob-Rb) activates JAK/STAT 
pathways. The activated JAKs phosphorylate tyrosine sites on the intracellular 
domain of the receptor, which serve as docking sites for the Src-homology domains 
(SH2, SH3) that occur in all of the STATs
86,93
. The phosphorylated intracellular 
domain then provides a binding site for a STAT protein. The activated STAT proteins 
dimerise and translocate to the nucleus, where they bind DNA and activate 
transcription. Ob-Rb activation may also phosphorylate JAK leading to the activation 
of insulin receptor substrate (IRS-1) and mitogen-activated protein kinase (MAPK). 
Upon leptin binding, the short form of the leptin receptor (OB-Ra) phosphorylates 
IRS-1 and consequently activates MAPK. The activation of MAPK leads to the 
activation of pp90 S6-K
95,96
. 
 
 Recently, a new family of cytokine-inducible inhibitors of signaling has been 
identified, including cytokine-inducible sequence (CIS) and suppressor-of-cytokine-
signalling-3 (SOCS3)
97,98-103
 CIS and SOCS3 may function as part of an intracellular 
negative-feedback loop, inhibiting JAK activity, and thereby switching off or 
dampening cytokine signal transduction.
101,102
 
 
 PERIPHERAL INTERACTIONS OF LEPTIN  
ADIPOSITY SIGNAL 
 Leptin and insulin are known to act as an adiposity signal  
 Leptin circulates at levels proportional to body fat 
 It enters the central nervous system (CNS) in proportion to its plasma 
concentration  
 Its receptors are found in brain neurons involved in regulating energy intake 
and expenditure 
 It controls food intake and energy expenditure by acting on receptors in the 
mediobasal hypothalamus
104
  
 
INTERACTION WITH AMYLIN 
 Co-administration of two neurohormones known to have a role in body weight 
control, amylin (produced by beta cells in the pancreas) and leptin (produced by fat 
cells), results in sustained, fat-specific weight loss in a leptin-resistant animal model 
of obesity.
105
 
 
LEPTIN AND HAEMOPOIESIS  
 It has recently been shown that Ob-R is expressed in haemopoietic cells and 
that leptin may be linked to the proliferation and differentiation of haemopoietic 
precursors.
89,106
  It is perhaps not surprising that leptin appears to have a role in 
haemopoiesis. Leptin structure is similar to the cytokines, containing four alpha 
helices. Furthermore, the Ob-R is a member of the type I cytokine receptor 
superfamily.  In cell culture studies, it appears that leptin has a mediation role, at least 
in murine myelocytic cells from bone marrow, in cell proliferation.
107
  
Studies have reported that relatively high concentrations of human leptin 
corresponding to plasma leptin levels in obese individuals, promoted platelet 
aggregation. At lower concentrations, leptin failed to potentiate agonist-induced 
platelet aggregation. This suggests that the leptin effect of potentiating platelet 
aggregation operates specifically in obese individuals and it may be a key coupling 
factor between obesity and the cardiovascular disease associated with syndrome X 
(which includes glucose intolerance, insulin insensitivity and abnormal fat 
distribution) and diabetes. Alternatively, these data may indicate that leptin action in 
platelets functions via an Ob-R-independent mechanism. 
 
LEPTIN AND ANGIOGENESIS  
 Further roles for leptin have been proposed in the circulatory system, 
including stimulation of endothelial cell growth and angiogenesis.
108,109
 Several 
studies have demonstrated that vascular endothelium expresses the long form of the 
receptor
110,111,108,109,112 
 (in rodents and humans
112
) and short
101,113,114
 form of the leptin 
receptor in rodents. 
 
 LEPTIN AND REPRODUCTION 
  Human ovary and prostate and murine ovary and embryo express mRNA for 
the leptin receptor.
86,89,115
 Although much of the evidence suggests a central site for 
the effects of leptin on the reproductive axis, a direct effect on the ovary has also been 
demonstrated, as leptin at physiological concentrations inhibits insulin-induced 
oestradiol production by granulosa cells from both small and large bovine 
follicles.
51,54,116
 This is an example of non-competitive antagonism between leptin and 
insulin, demonstrated in a range of tissues.  Expression of Ob-R has also been 
demonstrated in human granulosa cells.
117
 Furthermore,  Lindheim et al
118
 showed 
that a significant increase in circulating leptin levels occurred during controlled 
ovarian hyperstimulation, suggesting that leptin plays a role in follicular growth and 
maturation. 
 
 To date, human and animal studies suggest that placental leptin is likely to 
affect maternal, placental and fetal function through both autocrine and paracrine 
mechanisms. It is possible that placental leptin may have physiological effects on the 
placenta including  angiogenesis, growth and immunomodulation.
119
 Leptin may also 
be involved in regulation of fetal and uterine metabolism. 
 
LEPTIN IN FERTILITY  
 Hoggard and co-workers
57
 found that reproductive hormone levels are reduced 
in ob/ob females, suggesting a functional defect in the hypothalamic pituitary axis. 
Several independent reports have demonstrated that correction of leptin deficiency in 
ob/ob mice by peripheral injections of recombinant leptin activates the reproductive 
axis and restores fertility in both sexes.   
 
 Furthermore, in vitro studies have revealed that oestrogens increase leptin 
mRNA expression.
30,121
 Testosterone, in contrast, inhibits leptin gene expression in 
vivo and in vitro,
30,122
 possibly through a direct suppressive effect. Studies have also 
suggested that androgens and oestrogens modulate leptin expression at the mRNA 
level through sex steroid receptor-dependent transcriptional mechanisms.
30
 The study 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 9 – Hormonal Regulation of Energy Balance in Pregnancy 
of Jockenhovel et al
123
 indicated that testosterone substitution normalized elevated 
serum leptin levels in hypogonadal men. These investigators have concluded that 
interaction of testosterone and leptin might be part of a hypothalamic /pituitary / 
gonadal/adipose tissue axis that is involved in body weight maintenance and 
reproductive function. 
 
LEPTIN IN PREGNANCY   
 In females of most mammalian species, high leptin levels may signal the 
attainment of the sufficient long-term energy stores that are crucial for successful 
reproduction  (Figure 9).
124
 During human pregnancy, leptin levels were elevated 
throughout compared with the non-pregnant state.
53,125,126
 Furthermore, in both 
humans
53
 and mice,
124
 serum leptin was particularly elevated during the second and 
third trimesters. 
  
 Both the short and the long forms of leptin receptor were detected in the 
human placenta in early and in the full-term stages of gestation, using quantitative 
RT-PCR.
127
 Using in situ hybridization and immunohistochemistry, they also found 
that Ob-Rb was expressed by the apical membrane of the syncytiotrophoblasts. 
 
 
Hyperleptinemia of Pregnancy 
 At present there appears to be a number of possible explanations for the 
increase in leptin levels in pregnancy: increased production by maternal fat; increased 
expression by the placenta; and increased levels of binding protein(s) (also of 
placental origin in the case of the mouse
128
), in the maternal circulation.
57
 However, 
hyperleptinaemia during pregnancy is not associated with decreased food intake or a 
decline in metabolic efficiency, as might be expected given one of the roles of leptin 
is as a satiety factor. Explanations for this may be a possible pregnancy-induced state 
of leptin resistance, or a change in leptin bioavailability.
129,130
  It is interesting to note 
that some authors believe that the increase in leptin concentration during pregnancy is 
counter-intuitive as this is a period of increased nutritional demands and not one in 
which the actions of a satiety factor are expected to increase.
131
 Others have 
hypothesized that the soluble form of the leptin receptor mediates leptin actions 
during pregnancy, as the circulating concentrations of this protein are increased, 
especially in the mouse,
128
 although much less so in humans.
133
 Given the range of 
interactions between leptin and other hormone axes, and the complex pattern of 
central and peripheral pathways invoked, we hypothesize that, if leptin does in fact 
have a role as a satiety factor, this role is centrally mediated and may not be 
significantly modulated by the soluble leptin receptor. Interactions such as those 
between leptin and insulin, which modulate oxidation of FFA and lipogenesis  as part 
of the process which mobilizes energy reserves during pregnancy, are peripherally 
modulated and more influenced by the balance of energy reserve status and the 
demands of the fetus. Studies on the interaction of leptin binding protein status with 
plane of nutrition and energy reserve status during pregnancy will be required to 
confirm or refute this. 
 
 Studies suggest the possibility that leptin may be important for optimizing 
pregnancy outcome. Potential roles of leptin may include facilitation of endocrine 
responses to pregnancy, maintenance of maternal fuel homeostasis during a period of 
increased nutrient intake and requirement and/or optimization of fetal growth and 
development.The relative contributions of fetal-derived leptin and maternal leptin to 
maternal total leptin has recently been described by Linnemann et al
134
 using an in 
vitro perfusion technique. This study suggests that only 1-2% of placental leptin 
enters the fetal circulation, while approximately 98% enters the maternal circulation. 
Although not yet determined, the interaction of leptin with insulin may also be 
important in pregnancy. Leptin appears to act as a permissive factor with respect to its 
effects on insulin-mediated fuel storage in muscle and in the liver and on insulin-
mediated fuel utilization by muscle (see below).  Thus, one of the actions of fetal- and 
placental-derived leptin may be to act on maternal liver and muscle, changing the 
dynamics of fuel utilization. Particularly in the case where maternal nutrition may 
become limiting, and thus maternal leptin reduced; fetal- and placental-derived leptin 
would act on the maternal metabolism to ensure that fuel is preferentially utilized by 
the fetus, rather than rebuilding maternal stores. This hypothesis is consistent with the 
observation that leptin concentration is higher in arterial than in venous cord blood  
and suggests that both fetal- and placental-derived leptin targets maternal metabolism. 
 
 To consider this interaction further, we hypothesize that, following parturition, 
and the accompanying sudden decrease in leptin in the maternal circulation, insulin-
mediated fuel storage undergoes a rebound phase, in which maternal fuel stores are 
rapidly rebuilt. In some women, it may be that this rapid phase of increasing fuel 
storage is not counter-regulated and thus begins a phase in which adipocyte number 
increases, predisposing the subject to increased fat-to-lean ratio and in the longer-
term, in the case of repeated pregnancies, obesity. These factors are also likely to be 
intricately linked with lactation as serum leptin concentrations in lactating women are 
lower post-partum, but somewhat higher than in non-lactating women, further 
demonstrating a role for leptin in mobilizing fuel reserves.
135
 
 
  
LEPTIN EXPRESSION IN THE FETUS  
 The finding that leptin levels are increased in pregnancy
53,124,125,126
 has raised 
the possibility that leptin may play an important role in nutritional signaling between 
mother and the fetus during pregnancy. The expression of leptin by 
syncytiotrophoblasts
13,55,56
 suggests a role for leptin in nutrient transfer. Hoggard and 
co-workers
50
 studied leptin gene expression and localization of leptin protein in a 
number of tissues in the 14.5-day-old murine fetus by in situ hybridization and 
immunohistochemistry. High levels of leptin and its receptor expressed in fetal bone 
and cartilage suggested a role for leptin in bone or cartilage development. Leptin 
receptor mRNA and leptin receptor protein were also identified in leptomeninges and 
the choroid plexus of the fetal brain and in lung, kidney, heart and liver. 
 
 Schubring and co-workers
136
 found that maternal serum leptin concentrations 
do not correlate with birth weight. In contrast, leptin concentrations in umbilical cord 
blood correlated positively with birth weight and placental weight in humans.
136
 
Schubring et al
136
 demonstrated that leptin concentrations were higher in arterial cord 
blood than in venous cord blood, leading to the suggestion that leptin synthesis by 
fetal tissue may be greater than by placental tissue. However, evidence from 
Linnemann et al
134
 now suggests that fetal and placentally derived leptin may target 
maternal metabolism as outlined above. The high levels of expression of both leptin 
and leptin receptors in the placenta and fetus suggest that leptin plays a key role in 
fetal development. One possible role is that of a fetal growth factor, ie a signal to the 
fetus of the maternal energy status. Alternatively, as the concentration of leptin in 
arterial cord blood is higher than in venous cord blood, leptin may signal to the 
placenta the energy status of the fetus, and may have further actions on maternal 
metabolism, particularly if maternal energy stores become limiting. 
 
 
LEPTIN AND THE ONSET OF PUBERTY 
 The weight hypothesis of the development of puberty states that, when body 
weight reaches a certain level, puberty occurs. If rats are underfed, puberty is delayed, 
but with access to food rapid weight gain leads to onset of puberty.
137
 It has been 
shown that exogenous leptin accelerates the onset of puberty in normal female 
mice
124,138
 and normal prepubertal female rats.
139
 From this evidence it may be 
speculated that puberty is induced when fat stores reach a certain level, increasing the 
release of leptin from adipocytes into the bloodstream. Leptin may then act on 
hypothalamic cells to stimulate release of LHRH, thereby triggering gonadotropin 
release. The subsequent release of follicle-stimulating hormone (FSH) and LH 
stimulates gonadal steroid secretion, leading to development of the reproductive tract 
and induction of puberty. 
 
 However, several studies
140,141,142
 have demonstrated contrasting data which 
indicate that the timing of the onset of puberty in male Rhesus monkeys is not 
triggered by rising circulating leptin concentrations. Given the conflicting reports in 
the literature,
124,142,143
 it is likely that leptin is a factor permissive to the onset of 
puberty, and that, although some minimal threshold level of leptin is necessary to 
pubertal development, leptin is more likely not sufficient to initiate puberty. The 
interactions between leptin and oestrogens and androgens  indicate that leptin's role in 
the onset of puberty is mediated by different mechanisms in males and females and 
that further work is required to elucidate these differences. The notion that leptin is a 
permissive factor is supported by data which show that leptin is also expressed in 
skeletal muscle tissue.
144,86,82,89
 Thus, leptin may act as an indicator of general well-
being: that sufficient muscle mass has developed (and is in a phase of anabolic 
growth) and that a commensurate level of body fat has been deposited, such that it is 
favourable for puberty (and its consequences, such as pregnancy) to proceed. 
 
 
LEPTIN AND INSULIN 
 Insulin is an important regulator of energy homeostasis. It stimulates glucose, 
free fatty acid and amino acid uptake by tissues and tissue anabolism. It is not 
surprising that a link between leptin and insulin should exist in the regulation of 
energy homeostasis.  
 Leptin appears to act as a permissive factor with respect to its effects on 
insulin-mediated fuel storage in muscle and in the liver and on insulin-mediated fuel 
utilization by muscle.   
 
EFFECTS OF INSULIN ON LEPTIN 
  Current knowledge suggests that insulin plays a chronic role in the regulation 
of leptin gene expression and production by WAT. 
 
Effects of Hyperinsulinemia 
 Some studies have shown that hyperinsulinemia increased plasma leptin 
concentrations and gene expression in WAT in both rodents and humans.
145-153
 Recent 
studies have shown that humans and rodents with insulinoma also have increased 
plasma leptin and leptin mRNA and plasma leptin concentrations returned to normal 
after removal of the insulioma.
154-156
 Insulin appears to act directly at the level of the 
adipocyte by increasing leptin secretion and gene expression, perhaps due to increased 
glucose transport and metabolism.
158
 
 
Effects of Insulin Deficiency   
 Streptozotocin-induced insulin deficiency results in reduced circulating 
concentrations of leptin and mRNA and that suppression was rapidly reversed by 
treatment with insulin.
159,158
  
 
EFFECTS OF LEPTIN ON INSULIN SECRETION AND TISSUE 
SENSITIVITY TO INSULIN 
  In 1996, Kieffer et al102 reported that leptin receptors are expressed in the 
insulin producing -cells within the pancreatic  islets, suggesting that leptin might 
influence insulin secretion through a direct action on these cells. This hypothesis was 
investigated by several others,
160-164
 with apparently conflicting results.Thus,the 
leptin, insulin interaction is highly controversial. 
 
 Leptin impaired insulin-mediated stimulation of glucose transport, glycogen 
synthase activity, lipogenesis,  protein kinase A activation and protein synthesis in a 
dose-dependent manner.   Leptin inhibition of insulin-mediated glucose transport 
appears to be a direct (peripheral) relationship in adipocytes. However it appears to be 
centrally controlled in muscle tissue . 
 Other studies have found a direct link between plasma leptin concentration 
and measures of insulin sensitivity independent of the degree of body fatness.
160,165,166
 
High levels of leptin were associated with insulin resistance independent of BMI. In 
humans, it is still not clear whether the hyperinsulinemia that accompanies insulin 
resistance is associated with the higher leptin levels, so observed in some obese 
subjects with non-insulin-dependent diabetes mellitus (NIDDM)
167
 or polycystic 
ovary syndrome (PCOS).
168
 
 
 Furthermore, the mechanism underlying the contribution of leptin to insulin 
secretion as well as the physiological impact of leptin's nutrient stimulation effect 
remains to be studied in more detail. 
 
 Several studies have suggested that glucose is also an important regulator of 
leptin expression and secretion.
169,170
 Kamohara et al
171
 have demonstrated that  leptin 
administered  into wild-type mice increased glucose turnover and glucose uptake, 
independent of increase in plasma insulin. However, given that leptin modifies insulin 
sensitivity of muscle and liver to glucose uptake , probably via CNS control, it 
appears likely that glucose is regulated and is not a regulator. 
 
LEPTIN AND INSULIN SENSITIVITY OF SKELETAL MUSCLE  
 It is worthy to  note that skeletal muscle accounts for a large proportion of 
insulin-stimulated glucose uptake and whole body lipid oxidation and is the major 
contributing tissue to resting metabolic rate. Thus, muscle may be an important tissue 
for the expression of the juxtaposed interactions of leptin and insulin. 
 
 Recently it was reported that leptin directly stimulates fatty-acid oxidation in 
muscle by activating the 5'-AMP-activated protein kinase, an enzyme that 
phosphorylates and subsequently inactivates CoA carboxylase.
172
 Thus a direct 
mechanism for the action of leptin on fatty acid oxidation  has now been defined. 
EFFECT OF LEPTIN ON GLUCOSE TRANSPORT 
  Kamohara et al
171
 suggested that leptin may acutely increase skeletal muscle 
glucose uptake by an insulin-independent mechanism. Infusion of murine leptin into 
the  mice led to an increase in glucose turnover and 2-deoxyglucose uptake into 
skeletal muscle and increased whole-body glucose turnover and glucose oxidation, 
despite no change in plasma insulin or glucose concentrations.   
 
EFFECT OF LEPTIN ON LIPID METABOLISM 
  Muscle plays an important role in clearance of serum free fatty acids (FFA) 
and triacylglycerol (TAG) and in whole-body FFA oxidation. Muoio et al
173
 found 
that leptin  increased FFA oxidation in  muscle whereas insulin decreased muscle 
FFA oxidation . One interpretation of these data links the apparent differing responses 
of muscle and adipose tissue to the interaction between leptin and insulin: obese 
subjects, having proportionately greater fat mass, may show a direct peripheral effect 
of leptin suppressing insulin-mediated glucose transport in adipose tissue, while the 
lipid oxidation effects are mostly manifested in muscle tissue. On the other hand, in 
lean subjects, having much lower fat mass, most of the effects on turnover are 
manifested in muscle tissue, and the relativity of the circulating concentrations of 
leptin and insulin, being lower, would favour lower FFA oxidation in muscle of lean 
compared to obese subjects. This relationship would be further complicated by the 
generally increased insulin resistance of obese subjects. 
 
  Studies also indicate that leptin attenuates insulin's antioxidative, lipogenic 
actions on muscle FFA metabolism via a peripheral mechanism, while leptin 
mediation of insulin-stimulated glucose disposal appears to occur via a central 
mechanism. Furthermore, as skeletal muscle represents approximately 40% of the 
total body weight,  leptin-stimulated FFA oxidation in skeletal muscle may represent a 
very important anti-obesity mechanism independent of the central nervous system. 
 
INTERACTION OF LEPTIN WITH INSULIN-MEDIATED HEXOSAMINE 
SYNTHESIS 
 
 Several studies have demonstrated a clear interaction between intracellular 
hexosamine concentrations (in muscle and in fat) and insulin resistance, in the rodent 
model, using in vivo
175-178,144
 and in vitro
144,179
 methods. This interaction has also been 
demonstrated in vitro in both human myogenic cells
180
 and adipocytes.
175
 Importantly, 
in the rodent model, an increase in leptin gene expression was associated with insulin 
resistance and intracellular glucosamine concentrations.
144,179,181. 
 
 The hexosamine biosynthetic pathway is the primary source of the substrates 
for the glycosylation of (glyco-) proteins,
182
 and is hypothesized to be a cellular 
'sensor' of energy availability.
 175,176,144
 However, quantitatively, only 1-3% of 
incoming glucose ultimately enters the hexosamine pathway.
177,182
 An alternative 
perspective to this proposed model is that, in vivo, it is increased leptin which signals 
excess energy stores and that leptin-mediated damping of insulin actions (particularly 
in muscle) on both glucose and in this case hexosamines reduces the activity in these 
storage pathways. In this alternative model, as leptin concentration increases in 
response to increasing fat mass (muscle has already become loaded with glycogen and 
hexosamines), the actions of insulin on glucose and hexosamine storage become 
increasingly damped. Simultaneously, TAG and thus, fatty acids are preferentially 
utilized as an energy source. This leads to a brief discussion of leptin interaction with 
insulin resistance. 
 
LEPTIN AND INSULIN RESISTANCE IN MUSCLE  
 A vast majority of studies of insulin resistance concentrate upon insulin 
interactions with glucose, while less attention is paid to insulin-mediated fatty acid 
uptake, for which mechanisms are now becoming clarified.
183
, Although insulin 
actively increases free fatty acid uptake by muscle,
183,185,185
 it clearly inhibits 
oxidation of free fatty acids, an action which is suppressed by leptin.
186,173,187,188
 This 
partitioning of insulin actions, some of which appear to be synergistic with leptin 
actions, such as increased uptake of free fatty acids by a direct mechanism and uptake 
of glucose possibly via a CNS-mediated mechanism (above), and others of which may 
appear to be antagonistic to leptin actions, such as the effects on fatty acid oxidation 
186,173,187,188
 are difficult to resolve into a single model. However, it may be stated in 
broad terms that insulin is anabolic and tends to increase storage of fuels and amino 
acids, while leptin appears to mobilize TAG and modulate preferential utilization of 
fatty acids. Simultaneously, leptin inhibits insulin-mediated mechanisms of long-term 
glucose storage and oxidation. 
 
 It is this sub-set of insulin actions upon which many investigations of insulin 
resistance have focussed and it may be that the typical, many-fold increases in 
circulating leptin concentrations observed in obesity have profound effects only upon 
glucose-metabolism-linked peripheral insulin resistance through the mechanisms 
proposed here. Thus, more thorough investigations of the interaction of leptin and 
insulin in regulating both glucose and fatty acid oxidation are of paramount 
importance in clarifying the progression of obesity and the development of peripheral 
insulin resistance. 
 
INTERACTION OF LEPTIN WITH OTHER METABOLITES AND 
HORMONES 
 Recent studies have shown that free fatty acids (FFA) decrease leptin mRNA 
levels in adipocytes, suggesting that FFA are involved in the regulation of leptin 
production in adipocytes. However, regulation of FFA in vivo involves complex 
mechanisms mediated by a range of hormones including insulin, growth hormone and 
leptin. Thus, it is likely that these hormones  are the drivers of this interaction. 
 
LEPTIN AND GLUCOCORTICOIDS 
 Adipocyte culture studies have shown that glucocorticoids stimulate leptin 
gene expression. Glucocorticoid secretion is linked with meal times in normal humans 
and rodents, and is increased in Cushing's disease or by glucocorticoid administration 
to normal volunteers. In humans, glucocorticoids stimulate leptin gene expression and 
secretion independently of effects on food intake, although increases in insulin or 
lipogenesis associated with food intake may contribute to leptin production.  
  
 Mechanisms of glucocorticoid stimulation of plasma leptin is still unknown. 
Wabitsch and co-workers have postulated that glucocorticoids may influence leptin 
gene expression directly and independently of their differentiation-promoting effects 
on adipocytes or they can induce changes in plasma insulin sensitivity. De Vos et al 
have shown similar effects on leptin expression in rats.  However, a later study by the 
same group indicates that the leptin gene promoter region does not contain a binding 
site for the glucocorticoid receptor, thus the effect does not rely on the classical 
molecular mechanism of glucocorticoid receptor action. However, another possible 
mechanism includes modulation via the CNS, mediated by NPY.  
 
 INTERACTION OF LEPTIN  WITH THE GROWTH HORMONE AXIS AND 
OTHER CYTOKINES 
 Although most of the interactions of leptin with growth hormone are likely to 
be centrally mediated, interactions of leptin with major components of the growth 
hormone axis, such as insulin-like growth factor-1 (IGF-1), appear to be more direct . 
 
LEPTIN AND GROWTH HORMONE 
 Several groups have reported that leptin regulates growth hormone (GH) 
secretion in humans, rodents, sheep, and pigs. However, when isolated rat adipocytes 
were incubated with either GH or insulin-like growth factor-1 (IGF-1) alone, there 
was no effect on leptin secretion.
62
  
 
LEPTIN AND IGF-1  
 The effect of IGF-1 on the reduction of fat pad mass is most likely due to a 
suppression of insulin secretion and thus enhancement of fat mobilization and fatty 
acid (FA) oxidation. As a consequence, adipose tissue leptin mRNA and serum leptin 
concentrations decrease as well. 
 
LEPTIN AND OTHER CYTOKINES  
 The influence of cytokines on leptin mRNA expression and circulating 
concentrations has been investigated in human subjects. Interleukin-1 (IL-1) was 
found to induce leptin  levels directly or indirectly, by increasing the activity of the 
hypothalamic/pituitary axis. Mantzoros and co-workers reported a positive and 
independent association between tumour necrosis factor-  (TNF- ) levels and 
circulating leptin concentrations, suggesting that TNF-  may directly induce leptin 
gene expression in humans, as it does in rodents. These studies may implicate a role 
for leptin in the pathogenesis of cachexia that is accompanied by increased levels of 
cytokine in advanced stages of AIDS and cancer.  
 
LEPTIN RESISTANCE AND OBESITY 
 Although leptin is a circulating signal that reduces appetite, in general, obese 
people have an unusually high circulating concentration of leptin.
186
 These people are 
said to be resistant to the effects of leptin, in much the same way that people with type 
2 diabetes are resistant to the effects of insulin. The high sustained concentrations of 
leptin from the enlarged adipose stores result in leptin desensitization. The pathway of 
leptin control in obese people might be flawed at some point so the body doesn't 
adequately receive the satiety feeling subsequent to eating. 
  
  
 
 
 
AIM OF THE STUDY 
 
 
  
AIM OF THE STUDY 
 
 To assess leptin and C-peptide levels in Cord Blood of Infants born to 
Diabetic Mothers (GDM and type 2 DM mothers) 
 To measure the anthropometric measures of the newborn  
o Birth weight 
o Length of babies 
o Ponderal  index  
o Head circumference 
 To  find if there is any correlation between  leptin levels and the C-peptide 
levels 
 To find if the  leptin levels correlate  with the anthropometric measurements of 
the newborns 
 To find the correlation of C-peptide levels with the anthropometric 
measurements 
To assess  if there is any gender difference in  leptin levels (difference in leptin levels 
between male and female babies born to women of all three groups) 
  
  
 
 
MATERIALS AND 
METHODS 
  
MATERIALS AND METHODS 
 
STUDY POPULATION 
 
 After getting approval from  Ethical Committee of GGH, Chennai, the study 
was carried out in IOG & Hospital for women and children, Egmore, Chennai. 
Cases : 
The   study   sample   comprised 40 babies (20M,20 F) born to GDM mothers and 20 
babies(9M,11F) born to type2DM  mothers. GDM mothers were diagnosed with 
100gm glucose tolerance test (ADA Criteria). Both GDM and Type2 DM mothers 
were on treatment with diet modifications, exercise and insulin. 
Controls :  
Consists of 30 babies (15M,15F) born to non-diabetic mothers  
 
Inclusion   Criteria  
Mothers aged between 25-35 years and without any other medical complications of 
pregnancy 
 
Exclusion Criteria 
Mothers with complications like preeclampsia, preterm deliveries, twin pregnancies 
and other complications during labour were excluded 
 
Other Parameters Considered: 
 Gestational age : Calculated with LMP and USG findings in first trimester  
 Birth weight and placental weight measured 
 Ponderal index of babies measured using  birth weight and length of the babies 
[Weight (g) *100 / Length (Cm)
3
] 
 Head circumference of babies measured 
 
SAMPLE COLLECTION AND PROCESSING 
 10 mL of Cord blood was collected in plain tubes from umbilical vein with 
precautions to prevent hemolysis 
 Sample collection was completed in 1 month 
 Serum was separated and stored at -200C till analysis 
 Cord serum Leptin and C-peptide measured by ELISA 
 
ESTIMATION OF SERUM LEPTIN 
Methodology 
 Enzyme immunoassay method using leptin elisa kit from diagnostic biochem 
Canada (dbc labs) (Kit No CAN-L-4260) 
 
Principle of the Test 
 It is a two-step capture or ‗sandwich‘ type assay. It makes use of two highly 
specific monoclonal antibodies. A monoclonal antibody specific for leptin is 
immobilized onto the microwell plate and another monoclonal antibody specific for a 
different epitope of leptin is conjugated to biotin. In the first step leptin present in  the 
samples and standards is bound to the immobilized antibody and to the biotinylated 
antibody, thus forming a sandwich complex. Excess and unbound biotinylated 
antibody is removed by a washing step. In the second step, streptavidin-HRP is added 
which binds specifically to any bound biotinylated antibody. Again unbound 
streptavidin-HRP is removed by a washing step. Next the enzymes substrate TMB is 
added,  forming a blue coloured product that is directly proportional to the amount of 
leptin present. The enzymatic reaction is terminated by the addition of stopping 
solution,  converting the blue colour to a yellow colour. The absorbance is measured 
on a micotiter plate reader at 450nm. A set of standards is used to plot a standard 
curve from which the amount of leptin in patient samples and controls can be directly 
read.  
Reagents Provided 
1. Anti-Leptin Monoclonal Antibody Coated Microwell Plate –( One 96 well 
(12x6) monoclonal antibody-coated microwell plate)  
2. Monoclonal Anti-Leptin Biotin Conjugate( Monoclonal anti-leptin antibody 
conjugated to biotin )-10 ml/bottle 
3. Streptavidin-HRP Conjugate Concentrate( Streptavidin Conjugated to 
horseradish peroxidase )- 0.4 mL/bottle 
a. Preparation: We diluted 1:50 in assay buffer  (e.g. 40µL of 
concentrate in 2 mL of assay buffer). Since the  whole plate was used, 
we diluted 240 µL of concentrate in 12mL of assay buffer 
 
4. Leptin Calibrators (Six bottles -  0.5 ml / bottle) 
Calibrator Concentration Volume/Bottle 
Calibrator A 0 ng/mL 0.5 mL 
Calibrator B 1 ng/mL 0.5 mL 
Calibrator C 5 ng/mL 0.5 mL 
Calibrator D 10 ng/mL 0.5 mL 
Calibrator E 20 ng/mL 0.5 mL 
Calibrator F 50 ng/mL 0.5 mL 
Calibrator G 100 ng/mL 0.5 mL 
 
5. Control (One bottle - 0.5 mL/bottle) 
6. Wash Buffer Concentrate (One bottle - 50 mL/bottle) 
a. Preparation : We diluted 1:10 in distilled  water . Since the whole 
plate was used  we diluted 50ml of the wash buffer concentrate in       
450 ml of water 
7. Assay Buffer  (One bottle - 20 mL/bottle) 
8. TMB Substrate  (One bottle containing tetramethylbenzidine and hydrogen 
peroxide )- 16 mL/bottle 
9. Stopping Solution (One bottle containing 1M sulfuric acid - 6 mL/bottle) 
 
Assay Procedure 
1. All reagents were brought to room temperature before use 
2. Working solutions of the streptavidin-HRP conjugate and wash buffer were 
prepared 
3. 20µL of each calibrator, control and serum samples were added into 
correspondingly labelled wells  
4. 80µL of the monoclonal anti-leptin-biotin conjugate was added  into each 
well 
5. Incubated on a plate shaker (approximately 200 rpm) for 1 hour at room 
temperature 
6. The wells were washed 3 times with prepared wash buffer (300µL for each 
wash)  
7. 100µL of prepared streptavidin-HRP conjugate was added into each well 
8. Incubated on a plate shaker (approximately 200 rpm) for 30 minutes at 
room temperature 
9. The wells were washed  again in the same manner as step 6 
10. 100µL of TMB substrate was added into each well  
11. Incubated  on a plate shaker for 10-15 minutes at room temperature 
12. 50µL of stopping solution was added  into each well  
13. The  plate was read on a microwell plate reader at 450nm within 20 minutes 
after addition of the stopping solution 
Sensitivity 
 The limit of detection (LoD) for Leptin is 0.5 ng/mL 
 
Expected Normal Values 
 
 
Group 
Mean 
(ng/mL) 
Range 
(ng/mL) 
Lean Women 7.4 3.7-11.1 
Lean Men 3.8 2.0-5.6 
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ESTIMATION OF SERUM C PEPTIDE 
Methodology 
 Direct solid phase enzyme immunoassay from Diametra for quantitative 
determination of C-peptide in human serum. 
 
Principle 
 In this procedure, the immobilization takes place during the assay at the 
surface of a microplate well through the interaction of streptavidin (S.Avidin) coated 
on the well and exogenously added biotinylated monoclonal anti-C peptide antibody 
(Ab). Upon mixing monoclonal biotinylated antibody, the enzyme-labelled antibody 
and serum containing the native antigen (Ag), reaction results between the native 
antigen and the antibodies to form a soluble sandwich complex. The interaction is 
illustrated by the following equation: 
 
 
 
BtAb(m) = Biotinylated Monoclonal Antibody  (Excess Quantity) 
AgN = Native Antigen (Variable Quantity) 
EAb = Enzyme labelled Antibody (Excess Quantity) 
EAb –AgN – BtAb(m) = Antigen-Antibodies Sandwich Complex 
ka = Rate Constant of Association 
k-a = Rate Constant of Dissociation 
 
 Simultaneously, the complex is deposited to the well through the high affinity 
reaction of streptavidin and biotinylated antibody.  
 
Ka 
EAb + AgN + BtAb(m) <->EAb – AgN – BtAb(m) 
K-a 
This interaction is illustrated below: 
 
 
StreptavidinC.W. = Streptavidin immobilized on well  
Immobilized complex = sandwich complex bound to the well. 
 
 
 The enzyme activity in the antibody-bound fraction is directly proportional to 
the native antigen concentration. The activity of the enzyme present on the surface of 
the well is quantitated by reaction with a suitable substrate to produce colour. By 
utilizing several different calibrators of known antigen values, a dose response curve 
can be generated from which the antigen concentration of an unknown can be 
ascertained. 
 
Test Components 
1. C-peptide Standards 6x (1 vial = 2 mL) 
2. Conjugate  (Anti C-pep-HRP conjugate + Mouse-Anti-C-pep conjugate 
biotinylated) (1 bottle – 13 ml) 
3. Coated Microplate  (Microplate coated with streptavidin)   
4. TMB-substrate (1 bottle – 12 ml) 
5. Stop solution  (Sulphuric acid 0.15 mol/L) (1 bottle – 12 ml) 
6. Conc. Wash Solution 50x (1 vial) 20 ml (NaCl 9 gr/l; Tween20 1gr/l)  
 
DETECTION LIMIT 
 This method allows the quantitative determination of C-Peptide from 0.2 to 
10.0 ng/ml. 
EAb-AgN-BtAb(m) + StreptavidinC.W. => Immobilized Complex 
Preparation of the Standard (S0,S1,S2,S3,S4,S5) 
The standard has approx. the following concentration: 
 S0 S1 S2 S3 S4 S5 
ng/ml 0 0.2 1.0 2.0 5.0 10.0 
 
Each standard was reconstituted with 2.0 mL of distilled  water. 
Preparation of Wash Solution 
 We diluted the contents of concentrated wash solution 50x to 1000 mL with 
distilled water in a suitable storage container. 
 
Preparation of the Sample 
 The samples were stored at temperatures of -20°C .Frozen samples were 
thawed under tap water. 
 
Assay Procedure 
 
1. All reagents were brought to room temperature 
2. 50 µL of each standard prepared (0, 0.2, 1, 2, 5, 10 ng/ml) was added into 
appropriate wells in the microtiter plate. 
3. 50 µL  of serum samples were added in the other wells 
4. 100 µL  of the conjugate was then added to the wells containing standards and 
serum samples 
5. Incubated at room temperature for 2 hours 
6. Wells washed with 300 ml  of diluted wash solution 
7. Washing repeated another two times 
8. TMB substrate 100 µL is added to the wells 
9. Incubated at room temperature for 15 minutes 
10. 100 µL   stop solution added to the wells 
11. The absorbance was read at 450 nm 
 
Reference Value 
Adult (Normal) 0.7 – 1.9 ng/mL 
Sensitivity 
 The lowest detectable concentration of C-peptide that can be distinguished 
from the zero standard is 0.025 ng/mL at the 95 % confidence limit. 
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RESULTS  
  
Summary of Results 
The Various parameters evaluated namely birthweight, head circumference, length of 
babies, ponderal index, placental weight, gestational age, leptin & C-peptide levels in 
babies born to GDM, Type2DM and Non diabetic mothers are presented in Table 1-3 
The Mean and Standard deviation for the various parameters evaluated are presented 
in Table – 4 
 
Statistical Analysis 
 Statistical Analysis was done by Oneway ANOVA F-test for p-value (P<0.05 
is considered to be significant) 
 Bonferroni t-test was used for comparison of the levels of each parameter in 
various groups 
 Karl pearson‘s correlation coefficient was used to analyse the correlation 
between various parameters 
 
Table -4 shows comparison of leptin levels, C-peptide levels, birthweight, placental 
weight, ponderal index and head circumference among the three groups.  Oneway 
ANOVA is used for the comparison. Leptin and C-peptide levels are higher in cases 
than in controls.  The birthweight, placental weight, ponderal index and head 
circumference are also higher in cases than in controls. 
 
Table -5 shows the correlation of leptin with C-peptide, birthweight,  ponderal index, 
placental weight,  head circumference and gestational age in all the  groups.  Pearson 
Correlation is used here.  Except for gestational age, all the other parameters show a 
strong correlation with leptin in all the groups. 
Table -6 shows a strong correlation between leptin and C-peptide in all 3 groups.   
Table -7 shows a strong correlation of leptin with birthweight, ponderal index and 
head circumference in all 3 groups.   
Table – 8 shows a strong correlation of C-peptide with birthweight, ponderal index 
and head circumference in the various groups. 
Table -9 shows the difference in leptin levels between the male and female babies 
born to mothers of each group.  Student independent t-test is used for this purpose. 
The difference is significant only in babies of GDM population.  The difference is not 
statistically significant in babies of type 2 DM population and controls probably due 
to the small sample size of this population. 
Table -10 compares the leptin levels in male babies of all 3 groups and in female 
babies in the various groups. Oneway ANOVA is used here.  There is a significant 
increase in leptin in male babies of GDM and type 2 DM mothers than in controls and 
a similar increase of leptin in female babies of GDM and type 2 DM mothers 
compared to controls. 
Table -11 shows a comparison of birthweight between male and female babies of 
mothers of all 3 groups. Student independent t-test is used. There is no statistically 
significant difference in birthweight between male and female babies in each group. 
Table -12 shows a comparison of parity of mothers in all 3 groups. Chi square test is 
used here. There is no significance.  
 Table -13 shows a comparison of mode of delivery in all 3 groups. Higher proportion 
of caesarean section in GDM and DM mothers compared to controls probably due to 
macrosomia and other complications in them.

   
   
SL NO 
MOTHER’S 
AGE 
(YRS) 
PARITY 
GESTA 
TIONAL 
AGE 
( WEEKS) 
MODE OF 
DELIVERY 
SEX OF 
BABIES 
PLACENTAL 
WEIGHT 
(GM) 
BIRTH 
WEIGHT 
(KG) 
LENGTH 
OF 
BABIES 
(CM) 
PONDERAL 
INDEX 
HEAD 
CIRCUMFER
ENCE 
(CM) 
LEPTIN 
(ng/mL) 
CPEPTIDE 
(ng/mL) 
1 30 0 38 Vaginal M 465 2.40 46 2.466 34.50 18.75 1.20 
2 33 0 38 Caesarean F 543 4.40 51 3.317 36.30 80.70 3.30 
3 31 1 37 Vaginal M 453 2.50 47 2.408 34.00 9.40 1.33 
4 30 1 38 Vaginal M 464 2.50 47 2.408 34.60 23.60 1.10 
5 31 2 38 Vaginal M 487 2.70 48 2.441 34.70 28.78 1.40 
6 33 0 38 Caesarean F 547 4.30 50 3.440 35.80 76.90 3.30 
7 32 2 28 Vaginal M 505 2.90 48 2.622 35.00 26.40 1.40 
8 33 1 38 Caesarean F 559 4.00 50 3.200 35.60 64.80 3.10 
9 34 0 38 Caesarean F 543 3.60 50 2.880 35.30 58.14 2.90 
10 30 0 38 Caesarean F 555 3.30 49 2.805 35.00 33.31 2.60 
11 31 1 38 Caesarean F 516 3.20 49 2.720 35.00 34.00 2.20 
12 31 0 38 Caesarean F 521 3.10 49 2.635 35.00 30.16 2.20 
13 31 0 38 Caesarean M 532 3.40 49 2.890 35.40 41.50 2.30 
14 32 0 38 Caesarean M 545 3.60 50 2.880 35.70 48.23 2.40 
15 29 1 38 Caesarean F 500 2.90 49 2.465 35.00 26.50 1.90 
16 30 1 38 Caesarean F 480 2.60 48 2.351 34.60 19.37 1.70 
17 32 1 37 Caesarean F 436 2.10 45 2.305 33.40 8.41 1.00 
18 33 0 38 Vaginal F 578 4.50 51 3.392 36.10 83.50 3.20 
19 34 0 38 Caesarean M 548 3.70 50 2.960 35.70 65.40 2.40 
20 32 0 38 Caesarean M 562 3.90 50 3.120 35.70 68.60 2.50 
Table 2 – MASTER CHART TYPE2 DIABETES MELLITUS 
SL NO 
MOTHER’S 
AGE  (YRS) 
PARITY 
GESTATIONAL 
AGE 
(WEEKS) 
MODE OF 
DELIVERY 
SEX OF 
BABIES 
PLACENTAL 
WEIGHT 
(GM) 
BIRTH 
WEIGHT 
(KG) 
LENGTH 
OF 
BABIES 
(CM) 
PONDERAL 
INDEX 
HEAD 
CIRCUMFERE
NCE 
(CM) 
LEPTIN 
( ng/mL ) 
CPEPTIDE 
( ng/mL ) 
1 30 2 40 Vaginal M 450 2.40 46 2.466 34.00 11.53 1.10 
2 29 2 39 Vaginal M 480 3.00 49 2.550 35.00 20.10 1.30 
3 33 1 39 Vaginal M 436 2.10 46 2.157 33.50 2.43 0.80 
4 31 0 40 Caesarean F 546 3.40 49 2.890 34.20 43.18 1.50 
5 28 1 39 Vaginal F 500 2.60 47 2.504 34.80 18.69 1.00 
6 34 0 38 Vaginal M 432 2.20 46 2.260 33.40 6.27 0.70 
7 35 1 39 Vaginal F 427 2.30 46 2.363 33.60 12.31 0.80 
8 29 0 40 Caesarean M 510 3.10 49 2.635 35.00 26.05 1.20 
9 33 0 39 Vaginal M 440 2.30 46 2.363 33.50 9.32 0.60 
10 27 0 40 Caesarean M 513 3.60 50 2.880 35.70 42.17 1.60 
11 25 2 39 Vaginal F 475 2.60 47 2.504 34.50 20.58 1.10 
12 28 1 38 Vaginal F 470 2.40 46 2.466 33.80 15.49 1.00 
13 29 0 38 Vaginal M 455 2.40 46 2.466 34.00 13.62 1.30 
14 33 0 40 Caesarean F 530 3.60 50 2.880 35.60 48.22 1.50 
15 30 1 39 Caesarean F 513 3.20 48 2.894 35.00 40.94 1.30 
16 34 2 38 Vaginal F 447 2.50 47 2.408 34.00 10.40 0.60 
17 28 0 38 Vaginal M 458 2.50 47 2.408 34.00 14.76 0.80 
18 30 0 38 Caesarean F 469 2.50 47 2.408 34.70 16.74 0.70 
19 28 0 38 Vaginal F 440 2.20 46 2.260 33.30 3.82 0.70 
20 31 1 38 Caesarean M 515 2.90 48 2.622 34.60 23.86 1.20 
21 32 0 40 Caesarean F 520 3.60 49 3.060 35.40 52.79 1.50 
22 30 2 40 Caesarean M 516 3.20 48 2.894 34.60 34.51 1.40 
23 34 1 39 Caesarean M 543 3.30 49 2.805 35.20 31.46 1.50 
24 26 0 38 Caesarean M 465 2.50 47 2.408 34.00 13.20 0.90 
25 33 2 38 Vaginal F 437 2.30 47 2.215 33.40 13.72 0.70 
26 29 2 39 Vaginal M 450 2.30 46 2.363 34.00 5.96 0.80 
27 31 1 41 Caesarean F 546 3.30 49 2.805 35.00 36.12 1.40 
28 33 0 40 Vaginal M 500 3.10 48 2.803 34.70 26.27 1.30 
29 30 1 41 Caesarean F 540 3.70 49 3.145 35.80 50.46 1.60 
30 35 1 40 Caesarean F 551 3.60 50 2.880 35.60 51.00 1.60 
Table 3 – MASTER CHART - CONTROLS 
 RESULTS 
 
Parameters Group One 
way 
ANOVA 
Bonferroni 
t-test GDM TYPE 2 DM CONTROL 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
Leptin 40.31 22.71 42.32 24.09 23.87 15.48 
F=6.74 
P=0.002** 
Control Vs 
GDM, 
Type2 
C peptide 2.00 0.88 2.17 0.76 1.12 0.34 
F=17.89 
P=0.001*** 
Control Vs 
GDM, 
type2 
Birth Weight 3.21 .64 3.28 .71 2.82 .52 
F=4.47 
P=0.01** 
Control Vs 
GDM, 
Type 2 
Length 48.80 1.40 48.80 1.61 47.60 1.40 
F=6.85 
P=0.002** 
Control Vs 
GDM, 
Type2 
Ponderal 
Index 
2.738 0.357 2.785 0.363 2.592 0.269 
F=2.51 
P=0.09 
Control Vs 
GDM, 
Type2 
Head 
Circumferen
ce 
34.80 0.84 35.12 0.71 34.41 0.69 
F=5.40 
P=0.006** 
Control Vs 
Type2 
Placental 
Weight 
513.67 38.47 516.95 41.08 485.80 40.42 
F=5.36 
P=0.006*** 
Control Vs 
GDM, 
Type 2 
Gestational 
Age 
38.08 0.53 37.40 2.23 39.10 0.96 
F=12.29 
P=0.001*** 
Control Vs 
GDM, 
Type2 
Mothers Age 30.83 3.08 31.60 1.43 30.60 2.69 
F=0.89  
P=0.41 
- 
* significant  at P<0.05  ** Highly significant  at P<0.01   *** Very High significant  at P<0.001 
 
 
 
 
 
 
 
 
 
 
Table 4 – Comparison of Leptin, C Peptide Levels and Anthropometric Measures 
among various groups 
  
 
Pearson Correlation Coefficient 
 
Interpretation for r-value 
Pearson correlation coefficient is denoted by ―r‖ 
―r‖ always lies between -1  to  +1  
 
0.0 – 0.2   Poor correlation 
0.2 - 0.4    Fair correlation 
0.4 - 0.6    Moderate correlation 
0.6 – 0.8   Substantial correlation 
0.8 - 1.0    Strong correlation 
 
 
 
 
 
 
 
 
 
r =     N(XY) – (X) (Y) 
 
    [N X2 – (X)2] [NY2 – (Y)2] 
 
Table 5 - Correlation of Leptin with C-peptide and other Anthropometric 
measures 
 
 
Parameters 
Leptin 
GDM TYPE 2 DM CONTROL 
Pearsons 
Correlation 
Sig (2- 
tailed) 
Pearsons 
Correlation 
Sig (2- 
tailed) 
Pearsons 
Correlation 
Sig (2- 
tailed) 
C Peptide 0.96 0.001 0.95 0.001 0.96 0.001 
Birth Weight 0.98 0.001 0.98 0.001 0.97 0.001 
Length 0.85 0.001 0.88 0.001 0.88 0.001 
Ponderal Index 0.95 0.001 0.96 0.001 0.96 0.001 
Head 
Circumference 
0.94 0.001 0.92 0.001 0.80 0.001 
Gestational 
Age 
0.42 0.01 0.47 0.01 0.83 0.001 
Placental 
Weight 
0.92 0.001 0.92 0.001 0.90 0.001 
  
 
Group Parameter  Leptin C Peptide 
GDM 
Leptin 
Pearson Correlation 1 .957** 
Sig. (2-tailed) . .000 
N 40 40 
C Peptide 
Pearson Correlation 0.957** 1 
Sig. (2-tailed) .000 . 
N 40 40 
TYPE2 
DM 
Leptin 
Pearson Correlation 1 0.948** 
Sig. (2-tailed) . .000 
N 20 20 
C Peptide 
Pearson Correlation .948** 1 
Sig. (2-tailed) .000 . 
N 20 20 
CONTROL 
Leptin 
Pearson Correlation 1 .956** 
Sig. (2-tailed) . .000 
N 30 30 
C Peptide 
Pearson Correlation .956** 1 
Sig. (2-tailed) .000 . 
N 30 30 
** - Correlation is significant at the 0.01 level (2-tailed) 
 
Table 6 - Correlation of Leptin with C-peptide in all 3 Groups 
  
  
Group Parameters 
Leptin 
Correlation  
GDM 
 
Birth Weight 
Pearson Correlation .979(**) 
Sig. (2-tailed) .000 
N 40 
Length 
Pearson Correlation .851(**) 
Sig. (2-tailed) .000 
N 40 
Ponderal Index 
Pearson Correlation .951(**) 
Sig. (2-tailed) .000 
N 40 
Head 
Circumference 
Pearson Correlation .851(**) 
Sig. (2-tailed) .000 
N 40 
 
TYPE 2 DM 
 
 
 
 
 
 
 
 
 
 
 
Birth Weight 
 
Pearson Correlation .974(**) 
Sig. (2-tailed) .000 
N 20 
Length 
 
Pearson Correlation .881(**) 
Sig. (2-tailed) .000 
N 20 
Ponderal Index 
 
Pearson Correlation .962(**) 
Sig. (2-tailed) .000 
N 20 
Head 
Circumference 
Pearson Correlation .922(**) 
Sig. (2-tailed) .000 
N 20 
 
Control 
 
 
 
 
 
 
 
 
 
 
 
Birth Weight 
Pearson Correlation .969(**) 
Sig. (2-tailed) .000 
N 30 
Length 
Pearson Correlation .888(**) 
Sig. (2-tailed) .000 
N 30 
Ponderal Index 
Pearson Correlation .956(**) 
Sig. (2-tailed) .000 
N 30 
Head 
Circumference 
Pearson Correlation .801(**) 
Sig. (2-tailed) .000 
N 30 
** Correlation is significant at the 0.01 level (2-tailed)  
Table 7 – Correlation of Leptin with Anthropometric Measures 
 
 
 
  
Group Parameters 
C Peptide 
Correlation  
 GDM  
Birth Weight 
Pearson Correlation .976(**) 
Sig. (2-tailed) .000 
N 40 
Length 
Pearson Correlation .823(**) 
Sig. (2-tailed) .000 
N 40 
Ponderal Index 
 
Pearson Correlation .961(**) 
Sig. (2-tailed) .000 
N 40 
Head 
Circumference  
Pearson Correlation .871(**) 
Sig. (2-tailed) .000 
N 40 
 
Type 2 DM  
Birth Weight 
Pearson Correlation .956(**) 
Sig. (2-tailed) .000 
N 20 
Length 
Pearson Correlation .914(**) 
Sig. (2-tailed) .000 
N 20 
Ponderal Index 
Pearson Correlation .927(**) 
Sig. (2-tailed) .000 
N 20 
Head 
Circumference 
Pearson Correlation .868(**) 
Sig. (2-tailed) .000 
N 20 
 
Control  
Birth Weight 
Pearson Correlation .911(**) 
Sig. (2-tailed) .000 
N 30 
Length 
Pearson Correlation .830(**) 
Sig. (2-tailed) .000 
N 30 
Ponderal Index 
 
Pearson Correlation .906(**) 
Sig. (2-tailed) .000 
N 30 
Head 
Circumference  
Pearson Correlation .793(**) 
Sig. (2-tailed) .000 
N 30 
** Correlation is significant at the 0.01 level (2-tailed) 
Table 8 – Correlation of C-peptide with Anthropometric Measures 
 
 
  Group Sex N Mean 
Std. 
Deviation 
Student 
independent t-test 
LEPTIN 
GDM 
  
Male 20 32.3890 20.26697 t=2.32 P=0.03 
Female 20 48.2255 22.72249  
TYPE 2 
DM 
  
Male 9 36.7400 20.63124 t=0.93 P=0.36 
Female 11 46.8900 26.67511  
Control 
  
Male 15 18.7673 11.63725 t=1.88 P=0.07 
Female 15 28.9640 17.47705  
 
Table 9 – Comparison of Leptin in Male and Female Babies in each group 
 
 
 
 
Group 
Male Female 
Mean 
Standard 
Deviation 
Mean 
Standard 
Deviation 
GDM 32.39 20.27 48.23 22.72 
TYPE 2 DM 36.74 20.63 46.89 26.68 
Control 18.77 11.64 28.96 17.48 
Oneway 
ANOVA 
F=7.43 P=0.001 
Control Vs GDM, Type2 
GDM Vs Control 
Type2 Vs Control 
F=7.48 P=0.001 
Control Vs GDM, Type2 
GDM Vs Control 
Type2 Vs Control 
 
Table 10 – Comparison of  Leptin in Male and Female Babies among all groups 
 
  
          Table 11 - Birth Weight in Male and Female Babies of all Groups 
 
 
 
 
Group 
Chi-square 
test 
GDM TYPE 2 DM Control 
n % n % N % 
 
Parity 
 
.00 14 35.0% 11 55.0% 14 46.7% 
2=3.49 
P=0.48 
1.00 15 37.5% 7 35.0% 9 30.0% 
2.00 11 27.5% 2 10.0% 7 23.3% 
Table Total 40 100.0% 20 100.0% 30 100.0% 
 
Table 12 - Comparison of Parity of mothers in all groups 
 
 
Table 13 - Comparison of Mode of Delivery in all groups 
  
 Group sex N Mean 
Std. 
Deviation 
Student 
independent 
t-test 
Birth 
Weight 
GDM 
Male 20 3.055 .6186 
t=1.58 P=0.12 
Female 20 3.370 .6392 
TYPE 2 
DM 
Male 9 3.067 .5852 
t=1.23 P=0.23 
Female 11 3.455 .7815 
Control 
Male 15 2.727 .4667 
t=1.01 P=0.31 
Female 15 2.920 .5710 
 
Mode of 
Delivery 
Groups 
GDM TYPE 2 DM Control 
n % n % n % 
Caesarean 28 70.0% 14 70.0% 14 46.7% 
Vaginal 12 30.0% 6 30.0% 16 53.3% 
  
 
Figure 10 - Leptin among various groups 
 
 
 
Figure 11- C-peptide among various groups 
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Figure 12- Head Circumference among various groups 
 
 
 
Figure 13- BirthWeight among various groups 
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Figure 14- Mother’s Age among various groups 
 
 
 
Figure 15- Gestational Age among various groups 
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Figure 16- Placental Weight among various groups 
 
 
 
 
Figure 17 - Ponderal Index among various groups 
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Figure 18- Leptin Vs C-peptide in GDM cases 
 
Figure 19- Leptin Vs C-peptide in Type 2 DM 
 
Figure 20- Leptin Vs C-peptide in Controls 
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Figure 21- Gender Differences in Serum Leptin among various groups 
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Figure 22 - Leptin Vs Birthweight in GDM Cases 
 
 
 
 
Figure 23 -  Leptin Vs Birthweight in Type2 DM Cases 
 
 
 
 
 
Figure 24 -  Leptin Vs Birthweight in Controls 
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Figure 25 -  C-peptide Vs Birthweight in GDM Cases 
 
 
 
 
Figure 26 - C-peptide Vs Birthweight in Type2 DM Cases 
 
 
 
 
 
Figure 27 -  C-peptide Vs Birthweight in Controls 
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DISCUSSION   
 DISCUSSION 
 Exposure of the fetus to maternal diabetes results in characteristic changes in 
birth weight, adiposity and fetal insulin production. We have used cord  blood insulin 
and leptin as indicators of exposure to an abnormal intrauterine environment. 
Notably,  insulin  and leptin at birth  are significantly increased in our population, not 
only in offspring of mothers with type 2 diabetes, but also in offspring of mothers 
with GDM as seen in table-4.  
  
   Maternal diabetes is clearly associated with an increase in the  risk of type 2 
diabetes and obesity in the offspring, in keeping with in utero programming of 
disease
187,188
 and forming a ―vicious cycle of type 2 diabetes‖ 189. More recently, 
studies
190,191
 in hepatocyte nuclear factor-1α mutation carriers (maturity-onset 
diabetes of the young) have supported a role of the intrauterine environment in 
modifying the  risk of diabetes. Such studies are of interest, as our population is also 
believed to be at high genetic risk of obesity and type 2 diabetes and therefore likely 
to be prone to the same programming effects. How important is the finding of raised 
fetal insulin levels at birth? Importantly, the risk of later adverse metabolic 
consequences appears to relate to fetal insulin levels
192,193,194
.  In this context, our 
finding of increased concentrations of insulin in cord blood of offspring of mothers 
with type 2 diabetes and GDM suggests that such a cycle is also potentially present in 
our population. 
  The factors that increase fetal  leptin levels in macrosomia are not known. In 
rodents there is very little or no fetal adipose tissue; thus, the macrosomia may be a 
function of increased placental production, whereas in other animal models, fetal 
leptin correlates with adipose tissue mass.  There is a role for fetal and placental leptin 
 expression in the regulation of fetal growth, independent of maternal glucose. 
Placental leptin levels are increased in human diabetic pregnancies
196
 and decreased 
in pregnancies complicated by fetal growth retardation
197
.  Leptin‘s ability to 
influence fetal growth could have important implications for susceptibility to adult 
disease. 
           In our study, we have found a strong correlation between leptin and C –peptide 
levels in the babies of diabetic mothers, as seen in table-6.  A role for leptin in 
stimulating fetal pancreatic development has been suggested
198,199
, which could result 
in early insulin production and stimulate an increase in fetal growth. Alternatively, 
fetal hyperinsulinemia could stimulate increased fetal and placental leptin, which, in 
turn, could contribute to increased fetal growth in tissues expressing the leptin 
receptor.  Studies are currently underway to determine whether maternal leptin 
administration alters insulin and the b-cell gene expression profile in neonatal mice. 
           We have also found a significant increase in the birthweight, head 
circumference and other anthropometric measures in the infants of diabetic mothers 
and they show a strong correlation with leptin and C-peptide levels as evident from 
tables 7 and 8. 
                  In a study, Kostolova et al had shown no gender difference in leptin 
concentration in the offspring of DM mothers. But some studies have  suggested the 
differences in the leptin concentration between sexes.
200,201,202
 Various mechanisms 
have been postulated to explain this difference. The most accepted explanation is the 
differential adiposity between the genders
203,204,205
.   The gender dimorphism in leptin 
production which is observed in the very early life may also indicate the genetic 
difference in leptin production. Although we have observed  gender difference in 
leptin levels in our study , between male  and female babies born to women  in each 
 group, this difference is  significant only in the GDM group and not in the DM group 
as seen in Table-9.  This could be attributed to the reduced sample size in the DM 
group.  However, when we compare the leptin levels between male babies in all 3 
groups, there is a significant difference and we observe a similar significant 
difference when female babies between the 3 groups are compared, as seen in table-
10, suggesting that leptin in male babies of diabetic mothers is higher than in non-
diabetic mothers. Similarly leptin levels in female babies of diabetic mothers is higher 
than in non-diabetic mothers. 
             Table-11 compares the birthweight in male and female babies of each group. 
There is no significant difference in birthweight between the sexes. So, the increase in 
leptin levels in female babies of GDM group is independent of an increase in 
birthweight.  Hormonal factors could have contributed to the higher leptin levels. 
           The importance of GDM as a clinical entity has recently been demonstrated by 
an Australian randomized trial in which the identification and treatment of GDM 
significantly reduced the rate of fetal macrosomia and serious adverse perinatal 
outcome.
198    
Thus, the finding that fetal hyperinsulinemia is a common outcome of 
pregnancy in women with GDM in this population would support the importance of 
detection and careful monitoring of this group and suggests that similar studies be 
carried out in other groups. 
  
  
 
 
 
 
 
 
 
 
CONCLUSION 
  
 CONCLUSION 
 Statistically significant increase in Leptin  and C -peptide concentrations in 
newborns of both type  2 diabetes and GDM mothers is observed  
 Similar increase  in head circumference, birthweight  and other 
anthropometric measures in the  newborns of both type  2 diabetes and GDM 
mothers is present 
 There is a strong  correlation between leptin and C-peptide levels in newborns 
of GDM and type 2 DM  mothers 
 Leptin levels  and C-peptide levels correlate well with the neonatal 
anthropometric measurements (Birth weight and Head Circumference) 
 Leptin concentrations were significantly higher in the female babies in 
comparison to the male babies in the GDM population. But the difference is 
not significant in the DM group and controls and this could   be attributed to 
the smaller sample size in these groups 
      When the mother has type 2 diabetes / gestational diabetes mellitus 
(GDM), fetal hyperinsulinism is common despite treatment of disease and 
fetal leptin is also increased.  These effects are most pronounced in those 
women with Type2 DM.  This maternal diabetic environment could be a 
contributing factor for the infants to develop obesity and abnormal glucose 
tolerance later in life. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
SCOPE FOR FURTHER 
STUDY 
  
 SCOPE FOR FURTHER STUDY 
 Further studies examining the health of children of mothers with diabetes in this 
population and whether maternal glycemic control can impact upon this risk, are 
essential. 
 Leptin‘s ability to influence fetal growth could have important implications for 
susceptibility to adult disease and will be an important area for future research. 
 Regulation of leptin gene expression by androgens and estrogens can be studied.  
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